ID   S4A4_HUMAN              Reviewed;        1079 AA.
AC   Q9Y6R1; C4B714; O15153; Q8NEJ2; Q9H262; Q9NRZ1; Q9UIC0; Q9UIC1;
AC   Q9UP50;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   10-MAY-2017, entry version 140.
DE   RecName: Full=Electrogenic sodium bicarbonate cotransporter 1;
DE            Short=Sodium bicarbonate cotransporter;
DE   AltName: Full=Na(+)/HCO3(-) cotransporter;
DE   AltName: Full=Solute carrier family 4 member 4;
DE   AltName: Full=kNBC1;
GN   Name=SLC4A4; Synonyms=NBC, NBC1, NBCE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=9235899; DOI=10.1074/jbc.272.31.19111;
RA   Burnham C.E., Amlal H., Wang Z., Shull G.E., Soleimani M.;
RT   "Cloning and functional expression of a human kidney Na+:HCO3-
RT   cotransporter.";
RL   J. Biol. Chem. 272:19111-19114(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Pancreas;
RX   PubMed=9651366; DOI=10.1074/jbc.273.28.17689;
RA   Abuladze N., Lee I., Newman D., Hwang J., Boorer K., Pushkin A.,
RA   Kurtz I.;
RT   "Molecular cloning, chromosomal localization, tissue distribution, and
RT   functional expression of the human pancreatic sodium bicarbonate
RT   cotransporter.";
RL   J. Biol. Chem. 273:17689-17695(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Heart, Kidney, and Prostate;
RX   PubMed=10069984;
RA   Choi I., Romero M.F., Khandoudi N., Bril A., Boron W.F.;
RT   "Cloning and characterization of a human electrogenic Na+-HCO-3
RT   cotransporter isoform (hhNBC).";
RL   Am. J. Physiol. 276:C576-C584(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN CORNEAL
RP   ENDOTHELIAL CELLS, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RC   TISSUE=Corneal endothelium;
RX   PubMed=12907161; DOI=10.1016/S0014-4835(03)00150-7;
RA   Sun X.C., Bonanno J.A.;
RT   "Identification and cloning of the Na/HCO3- cotransporter (NBC) in
RT   human corneal endothelium.";
RL   Exp. Eye Res. 77:287-295(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Skeletal muscle;
RA   Pushkin A., Abuladze N., Kurtz I.;
RT   "Homo sapiens sodium bicarbonate cotransporter NBC1 splice variant.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RA   Yamada H., Nagayoshi A., Kuroda Y., Mizutani A., Ando H., Seki G.,
RA   Mikoshiba K.;
RT   "cDNA cloning and characterization of human sodium bicarbonate
RT   cotransporter, bNBC, a brain type splicing variant of SLC4A4 gene.";
RL   Submitted (NOV-2008) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   REGULATION, MUTAGENESIS OF SER-1026, AND PHOSPHORYLATION AT SER-1026.
RX   PubMed=11744745; DOI=10.1113/jphysiol.2001.012956;
RA   Gross E., Hawkins K., Pushkin A., Sassani P., Dukkipati R.,
RA   Abuladze N., Hopfer U., Kurtz I.;
RT   "Phosphorylation of Ser(982) in the sodium bicarbonate cotransporter
RT   kNBC1 shifts the HCO(3)(-):Na(+) stoichiometry from 3:1 to 2:1 in
RT   murine proximal tubule cells.";
RL   J. Physiol. (Lond.) 537:659-665(2001).
RN   [10]
RP   ERRATUM.
RA   Gross E., Hawkins K., Pushkin A., Sassani P., Dukkipati R.,
RA   Abuladze N., Hopfer U., Kurtz I.;
RL   J. Physiol. (Lond.) 538:1003-1003(2002).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=11743927; DOI=10.1016/S0003-9969(01)00098-X;
RA   Park K., Hurley P.T., Roussa E., Cooper G.J., Smith C.P., Thevenod F.,
RA   Steward M.C., Case R.M.;
RT   "Expression of a sodium bicarbonate cotransporter in human parotid
RT   salivary glands.";
RL   Arch. Oral Biol. 47:1-9(2002).
RN   [12]
RP   REGULATION, MUTAGENESIS OF ASP-1030; ASP-1032 AND ASP-1033, AND
RP   INTERACTION WITH CA2.
RX   PubMed=12411514; DOI=10.1113/jphysiol.2002.029777;
RA   Gross E., Pushkin A., Abuladze N., Fedotoff O., Kurtz I.;
RT   "Regulation of the sodium bicarbonate cotransporter kNBC1 function:
RT   role of Asp(986), Asp(988) and kNBC1-carbonic anhydrase II binding.";
RL   J. Physiol. (Lond.) 544:679-685(2002).
RN   [13]
RP   GLYCOSYLATION.
RX   PubMed=12604466; DOI=10.1152/ajprenal.00131.2002;
RA   Choi I., Hu L., Rojas J.D., Schmitt B.M., Boron W.F.;
RT   "Role of glycosylation in the renal electrogenic Na+-HCO3-
RT   cotransporter (NBCe1).";
RL   Am. J. Physiol. 284:F1199-F1206(2003).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=14559244; DOI=10.1016/j.bbrc.2003.09.147;
RA   Yamada H., Yamazaki S., Moriyama N., Hara C., Horita S., Enomoto Y.,
RA   Kudo A., Kawakami H., Tanaka Y., Fujita T., Seki G.;
RT   "Localization of NBC-1 variants in human kidney and renal cell
RT   carcinoma.";
RL   Biochem. Biophys. Res. Commun. 310:1213-1218(2003).
RN   [15]
RP   TOPOLOGY.
RX   PubMed=12534288; DOI=10.1021/bi026826q;
RA   Tatishchev S., Abuladze N., Pushkin A., Newman D., Liu W., Weeks D.,
RA   Sachs G., Kurtz I.;
RT   "Identification of membrane topography of the electrogenic sodium
RT   bicarbonate cotransporter pNBC1 by in vitro
RT   transcription/translation.";
RL   Biochemistry 42:755-765(2003).
RN   [16]
RP   REGULATION, INTERACTION WITH CA2 AND CA4, AND MUTAGENESIS OF GLY-767.
RX   PubMed=14567693; DOI=10.1021/bi0353124;
RA   Alvarez B.V., Loiselle F.B., Supuran C.T., Schwartz G.J., Casey J.R.;
RT   "Direct extracellular interaction between carbonic anhydrase IV and
RT   the human NBC1 sodium/bicarbonate co-transporter.";
RL   Biochemistry 42:12321-12329(2003).
RN   [17]
RP   REGULATION, MUTAGENESIS OF THR-49 AND SER-1026, AND PHOSPHORYLATION AT
RP   THR-49.
RX   PubMed=12730338; DOI=10.1113/jphysiol.2003.042226;
RA   Gross E., Fedotoff O., Pushkin A., Abuladze N., Newman D., Kurtz I.;
RT   "Phosphorylation-induced modulation of pNBC1 function: distinct roles
RT   for the amino- and carboxy-termini.";
RL   J. Physiol. (Lond.) 549:673-682(2003).
RN   [18]
RP   TISSUE SPECIFICITY.
RX   PubMed=15329059; DOI=10.1111/j.1365-201X.2004.01297.x;
RA   Kristensen J.M., Kristensen M., Juel C.;
RT   "Expression of Na+/HCO3- co-transporter proteins (NBCs) in rat and
RT   human skeletal muscle.";
RL   Acta Physiol. Scand. 182:69-76(2004).
RN   [19]
RP   MUTAGENESIS OF PHE-1057, AND SUBCELLULAR LOCATION.
RX   PubMed=15273250; DOI=10.1074/jbc.M405780200;
RA   Li H.C., Worrell R.T., Matthews J.B., Husseinzadeh H., Neumeier L.,
RA   Petrovic S., Conforti L., Soleimani M.;
RT   "Identification of a carboxyl-terminal motif essential for the
RT   targeting of Na+-HCO-3 cotransporter NBC1 to the basolateral
RT   membrane.";
RL   J. Biol. Chem. 279:43190-43197(2004).
RN   [20]
RP   INTERACTION WITH CA2, AND MUTAGENESIS OF 1002-LEU--ASN-1004 AND
RP   1030-ASP--ASP-1033.
RX   PubMed=15218065; DOI=10.1113/jphysiol.2004.065110;
RA   Pushkin A., Abuladze N., Gross E., Newman D., Tatishchev S., Lee I.,
RA   Fedotoff O., Bondar G., Azimov R., Ngyuen M., Kurtz I.;
RT   "Molecular mechanism of kNBC1-carbonic anhydrase II interaction in
RT   proximal tubule cells.";
RL   J. Physiol. (Lond.) 559:55-65(2004).
RN   [21]
RP   INTERACTION WITH CA4.
RX   PubMed=15563508; DOI=10.1093/hmg/ddi023;
RA   Yang Z., Alvarez B.V., Chakarova C., Jiang L., Karan G.,
RA   Frederick J.M., Zhao Y., Sauve Y., Li X., Zrenner E., Wissinger B.,
RA   Den Hollander A.I., Katz B., Baehr W., Cremers F.P., Casey J.R.,
RA   Bhattacharya S.S., Zhang K.;
RT   "Mutant carbonic anhydrase 4 impairs pH regulation and causes retinal
RT   photoreceptor degeneration.";
RL   Hum. Mol. Genet. 14:255-265(2005).
RN   [22]
RP   MUTAGENESIS OF TYR-477; ASP-493; ALA-494; GLU-503; SER-504; GLU-536;
RP   GLU-552; ARG-554; ARG-582; GLU-586; ASP-599; ALA-600; LYS-602;
RP   LYS-603; ASP-691; PHE-700; LYS-711; LYS-712; LYS-714; THR-715;
RP   THR-721; ARG-724; LYS-725; SER-728; ASP-729; ASP-743; ASP-749;
RP   LYS-752; ARG-766; GLU-775; ASP-798; 808-ARG--LYS-809;
RP   814-LYS--LYS-815; HIS-820; ASP-822; HIS-851; ASP-853;
RP   858-GLU--GLU-860; 875-GLU--ARG-877; LYS-898; 925-ARG--LYS-927;
RP   ARG-948; ARG-949; HIS-951; LYS-968 AND ARG-987.
RX   PubMed=15817634; DOI=10.1113/jphysiol.2005.084988;
RA   Abuladze N., Azimov R., Newman D., Sassani P., Liu W., Tatishchev S.,
RA   Pushkin A., Kurtz I.;
RT   "Critical amino acid residues involved in the electrogenic sodium-
RT   bicarbonate cotransporter kNBC1-mediated transport.";
RL   J. Physiol. (Lond.) 565:717-730(2005).
RN   [23]
RP   FUNCTION, FUNCTION (ISOFORM 2), AND INTERACTION WITH AHCYL1 (ISOFORM
RP   1).
RX   PubMed=16769890; DOI=10.1073/pnas.0602250103;
RA   Shirakabe K., Priori G., Yamada H., Ando H., Horita S., Fujita T.,
RA   Fujimoto I., Mizutani A., Seki G., Mikoshiba K.;
RT   "IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein,
RT   specifically binds to and activates pancreas-type Na+/HCO3-
RT   cotransporter 1 (pNBC1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:9542-9547(2006).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-254; SER-257 AND
RP   SER-1034, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-641 AND ASN-661.
RX   PubMed=25568315; DOI=10.1074/jbc.M114.619320;
RA   Zhu Q., Kao L., Azimov R., Abuladze N., Newman D., Kurtz I.;
RT   "Interplay between disulfide bonding and N-glycosylation defines SLC4
RT   Na+-coupled transporter extracellular topography.";
RL   J. Biol. Chem. 290:5391-5404(2015).
RN   [26]
RP   VARIANTS PRTA-OA SER-342 AND HIS-554.
RX   PubMed=10545938; DOI=10.1038/15440;
RA   Igarashi T., Inatomi J., Sekine T., Cha S.H., Kanai Y., Kunimi M.,
RA   Tsukamoto K., Satoh H., Shimadzu M., Tozawa F., Mori T., Shiobara M.,
RA   Seki G., Endou H.;
RT   "Mutations in SLC4A4 cause permanent isolated proximal renal tubular
RT   acidosis with ocular abnormalities.";
RL   Nat. Genet. 23:264-266(1999).
RN   [27]
RP   VARIANT PRTA-OA LEU-471.
RX   PubMed=15471865; DOI=10.1074/jbc.M406591200;
RA   Dinour D., Chang M.-H., Satoh J., Smith B.L., Angle N., Knecht A.,
RA   Serban I., Holtzman E.J., Romero M.F.;
RT   "A novel missense mutation in the sodium bicarbonate cotransporter
RT   (NBCe1/SLC4A4) causes proximal tubular acidosis and glaucoma through
RT   ion transport defects.";
RL   J. Biol. Chem. 279:52238-52246(2004).
RN   [28]
RP   VARIANTS PRTA-OA SER-342; LEU-471 AND HIS-554, AND MUTAGENESIS OF
RP   GLU-135.
RX   PubMed=15713912; DOI=10.1152/ajprenal.00032.2005;
RA   Li H.C., Szigligeti P., Worrell R.T., Matthews J.B., Conforti L.,
RA   Soleimani M.;
RT   "Missense mutations in Na+:HCO3- cotransporter NBC1 show abnormal
RT   trafficking in polarized kidney cells: a basis of proximal renal
RT   tubular acidosis.";
RL   Am. J. Physiol. 289:F61-F71(2005).
RN   [29]
RP   VARIANTS PRTA-OA SER-342; SER-529; HIS-554; VAL-843 AND CYS-925.
RX   PubMed=15930088; DOI=10.1681/ASN.2004080667;
RA   Horita S., Yamada H., Inatomi J., Moriyama N., Sekine T., Igarashi T.,
RA   Endo Y., Dasouki M., Ekim M., Al-Gazali L., Shimadzu M., Seki G.,
RA   Fujita T.;
RT   "Functional analysis of NBC1 mutants associated with proximal renal
RT   tubular acidosis and ocular abnormalities.";
RL   J. Am. Soc. Nephrol. 16:2270-2278(2005).
RN   [30]
RP   VARIANT PRTA-OA PRO-566, CHARACTERIZATION OF VARIANT PRTA-OA PRO-566,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16636648;
RA   Demirci F.Y., Chang M.H., Mah T.S., Romero M.F., Gorin M.B.;
RT   "Proximal renal tubular acidosis and ocular pathology: a novel
RT   missense mutation in the gene (SLC4A4) for sodium bicarbonate
RT   cotransporter protein (NBCe1).";
RL   Mol. Vis. 12:324-330(2006).
RN   [31]
RP   VARIANT PRTA-OA ARG-530, CHARACTERIZATION OF VARIANTS PRTA-OA SER-342
RP   SER-529; ARG-530 AND PRO-566, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17661077; DOI=10.1007/s00424-007-0319-y;
RA   Suzuki M., Vaisbich M.H., Yamada H., Horita S., Li Y., Sekine T.,
RA   Moriyama N., Igarashi T., Endo Y., Cardoso T.P., de Sa L.C.,
RA   Koch V.H., Seki G., Fujita T.;
RT   "Functional analysis of a novel missense NBC1 mutation and of other
RT   mutations causing proximal renal tubular acidosis.";
RL   Pflugers Arch. 455:583-593(2008).
CC   -!- FUNCTION: Electrogenic sodium/bicarbonate cotransporter with a
CC       Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3. May regulate
CC       bicarbonate influx/efflux at the basolateral membrane of cells and
CC       regulate intracellular pH. {ECO:0000269|PubMed:10069984,
CC       ECO:0000269|PubMed:12907161, ECO:0000269|PubMed:16636648,
CC       ECO:0000269|PubMed:16769890, ECO:0000269|PubMed:17661077,
CC       ECO:0000269|PubMed:9235899, ECO:0000269|PubMed:9651366}.
CC   -!- FUNCTION: Isoform 2: May have a higher activity than isoform 1.
CC       {ECO:0000269|PubMed:16769890}.
CC   -!- ENZYME REGULATION: Inhibited by stilbene derivatives and regulated
CC       by cyclic AMP.
CC   -!- SUBUNIT: Interacts with CA2/carbonic anhydrase 2 and CA4/carbonic
CC       anhydrase 4 which may regulate transporter activity
CC       (PubMed:12411514, PubMed:14567693, PubMed:15218065,
CC       PubMed:15563508). Isoform 1 but not isoform 2 interacts with
CC       AHCYL1 (via PEST domain when phosphorylated); the interaction
CC       increases SLC4A4 isoform 1 activity (PubMed:16769890). Interacts
CC       with AHCYL2 (By similarity). {ECO:0000250|UniProtKB:O88343,
CC       ECO:0000250|UniProtKB:Q9GL77, ECO:0000269|PubMed:12411514,
CC       ECO:0000269|PubMed:14567693, ECO:0000269|PubMed:15218065,
CC       ECO:0000269|PubMed:15563508, ECO:0000269|PubMed:16769890}.
CC   -!- INTERACTION:
CC       P48283:CA4 (xeno); NbExp=2; IntAct=EBI-6859278, EBI-6859264;
CC   -!- SUBCELLULAR LOCATION: Basolateral cell membrane
CC       {ECO:0000269|PubMed:12907161, ECO:0000269|PubMed:15273250,
CC       ECO:0000269|PubMed:16636648, ECO:0000269|PubMed:17661077}; Multi-
CC       pass membrane protein {ECO:0000269|PubMed:12907161,
CC       ECO:0000269|PubMed:15273250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=hcNBC, hhNBC, hNBC1, pNBC, pNCB1, pNBC-1, NBC1b;
CC         IsoId=Q9Y6R1-1; Sequence=Displayed;
CC       Name=2; Synonyms=hkNBC, hkNBCe1, kNBC, kNBC1, kNBC-1, NBC1a;
CC         IsoId=Q9Y6R1-2; Sequence=VSP_016704, VSP_016705;
CC       Name=3;
CC         IsoId=Q9Y6R1-3; Sequence=VSP_016704, VSP_016705, VSP_016706,
CC                                  VSP_016707;
CC       Name=4;
CC         IsoId=Q9Y6R1-4; Sequence=VSP_016708;
CC       Name=5;
CC         IsoId=Q9Y6R1-5; Sequence=VSP_041003;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed in pancreas and to a
CC       lower extent in heart, skeletal muscle, liver, parotid salivary
CC       glands, prostate, colon, stomach, thyroid, brain and spinal chord.
CC       Corneal endothelium cells express only isoform 1 (at protein
CC       level). Isoform 2 is specifically expressed in kidney at the level
CC       of proximal tubules. {ECO:0000269|PubMed:10069984,
CC       ECO:0000269|PubMed:11743927, ECO:0000269|PubMed:12907161,
CC       ECO:0000269|PubMed:14559244, ECO:0000269|PubMed:15329059,
CC       ECO:0000269|PubMed:9235899, ECO:0000269|PubMed:9651366}.
CC   -!- PTM: Phosphorylation of Ser-1026 by PKA increases the binding of
CC       CA2 and changes the Na(+):HCO3(-) stoichiometry of the transporter
CC       from 3:1 to 2:1. Phosphorylated in presence of STK39 and
CC       dephosphorylated in presence of PP1 phosphatase; phosphorylation
CC       seems to inhibit SLC4A4 activity. {ECO:0000250|UniProtKB:O88343,
CC       ECO:0000269|PubMed:11744745, ECO:0000269|PubMed:12730338}.
CC   -!- PTM: N-glycosylation is not necessary for the transporter basic
CC       functions. {ECO:0000269|PubMed:12604466}.
CC   -!- DISEASE: Renal tubular acidosis, proximal, with ocular
CC       abnormalities and mental retardation (pRTA-OA) [MIM:604278]: An
CC       extremely rare autosomal recessive syndrome characterized by short
CC       stature, profound proximal renal tubular acidosis, mental
CC       retardation, bilateral glaucoma, cataracts and bandkeratopathy.
CC       pRTA is due to a failure of the proximal tubular cells to reabsorb
CC       filtered bicarbonate from the urine, leading to urinary
CC       bicarbonate wasting and subsequent acidemia.
CC       {ECO:0000269|PubMed:10545938, ECO:0000269|PubMed:15471865,
CC       ECO:0000269|PubMed:15713912, ECO:0000269|PubMed:15930088,
CC       ECO:0000269|PubMed:16636648, ECO:0000269|PubMed:17661077}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Note=Loss of interaction with and stimulation by CA4 is
CC       the cause of retinitis pigmentosa type 17 (RP17).
CC   -!- SIMILARITY: Belongs to the anion exchanger (TC 2.A.31) family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF007216; AAC51645.1; -; mRNA.
DR   EMBL; AF011390; AAC39840.1; -; mRNA.
DR   EMBL; AF053753; AAF21718.1; -; mRNA.
DR   EMBL; AF053754; AAF21719.1; -; mRNA.
DR   EMBL; AF069510; AAD42020.1; -; mRNA.
DR   EMBL; AF310248; AAG47773.1; -; mRNA.
DR   EMBL; AF157492; AAF80343.1; -; mRNA.
DR   EMBL; AB470072; BAH58226.1; -; mRNA.
DR   EMBL; AC019089; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079230; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC096713; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC110783; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC112226; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC030977; AAH30977.1; -; mRNA.
DR   CCDS; CCDS3549.1; -. [Q9Y6R1-2]
DR   CCDS; CCDS43236.1; -. [Q9Y6R1-1]
DR   CCDS; CCDS47071.1; -. [Q9Y6R1-5]
DR   RefSeq; NP_001091954.1; NM_001098484.2. [Q9Y6R1-1]
DR   RefSeq; NP_003750.1; NM_003759.3. [Q9Y6R1-2]
DR   UniGene; Hs.5462; -.
DR   ProteinModelPortal; Q9Y6R1; -.
DR   BioGrid; 114219; 1.
DR   DIP; DIP-59373N; -.
DR   IntAct; Q9Y6R1; 5.
DR   STRING; 9606.ENSP00000393557; -.
DR   DrugBank; DB01390; Sodium bicarbonate.
DR   TCDB; 2.A.31.2.12; the anion exchanger (ae) family.
DR   iPTMnet; Q9Y6R1; -.
DR   PhosphoSitePlus; Q9Y6R1; -.
DR   SwissPalm; Q9Y6R1; -.
DR   BioMuta; SLC4A4; -.
DR   DMDM; 74721543; -.
DR   PaxDb; Q9Y6R1; -.
DR   PeptideAtlas; Q9Y6R1; -.
DR   PRIDE; Q9Y6R1; -.
DR   DNASU; 8671; -.
DR   Ensembl; ENST00000264485; ENSP00000264485; ENSG00000080493. [Q9Y6R1-1]
DR   Ensembl; ENST00000340595; ENSP00000344272; ENSG00000080493. [Q9Y6R1-2]
DR   Ensembl; ENST00000351898; ENSP00000307349; ENSG00000080493. [Q9Y6R1-4]
DR   Ensembl; ENST00000425175; ENSP00000393557; ENSG00000080493. [Q9Y6R1-5]
DR   Ensembl; ENST00000512686; ENSP00000422400; ENSG00000080493. [Q9Y6R1-3]
DR   GeneID; 8671; -.
DR   KEGG; hsa:8671; -.
DR   UCSC; uc003hfy.4; human. [Q9Y6R1-1]
DR   CTD; 8671; -.
DR   DisGeNET; 8671; -.
DR   GeneCards; SLC4A4; -.
DR   HGNC; HGNC:11030; SLC4A4.
DR   HPA; CAB022493; -.
DR   HPA; HPA035628; -.
DR   HPA; HPA035629; -.
DR   MalaCards; SLC4A4; -.
DR   MIM; 603345; gene.
DR   MIM; 604278; phenotype.
DR   neXtProt; NX_Q9Y6R1; -.
DR   OpenTargets; ENSG00000080493; -.
DR   Orphanet; 93607; Autosomal recessive proximal renal tubular acidosis.
DR   PharmGKB; PA35898; -.
DR   eggNOG; KOG1172; Eukaryota.
DR   eggNOG; ENOG410XPHD; LUCA.
DR   GeneTree; ENSGT00760000119021; -.
DR   HOVERGEN; HBG004326; -.
DR   InParanoid; Q9Y6R1; -.
DR   KO; K13575; -.
DR   OMA; VCSFMAL; -.
DR   PhylomeDB; Q9Y6R1; -.
DR   TreeFam; TF313630; -.
DR   Reactome; R-HSA-425381; Bicarbonate transporters.
DR   ChiTaRS; SLC4A4; human.
DR   GeneWiki; SLC4A4; -.
DR   GenomeRNAi; 8671; -.
DR   PRO; PR:Q9Y6R1; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000080493; -.
DR   CleanEx; HS_SLC4A4; -.
DR   ExpressionAtlas; Q9Y6R1; baseline and differential.
DR   Genevisible; Q9Y6R1; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005452; F:inorganic anion exchanger activity; IEA:InterPro.
DR   GO; GO:0008510; F:sodium:bicarbonate symporter activity; IMP:UniProtKB.
DR   GO; GO:0015701; P:bicarbonate transport; TAS:Reactome.
DR   GO; GO:0051453; P:regulation of intracellular pH; IBA:GO_Central.
DR   GO; GO:0006814; P:sodium ion transport; IDA:UniProtKB.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   Gene3D; 3.40.930.10; -; 1.
DR   InterPro; IPR013769; Band3_cytoplasmic_dom.
DR   InterPro; IPR011531; HCO3_transpt_C.
DR   InterPro; IPR003020; HCO3_transpt_euk.
DR   InterPro; IPR003024; Na/HCO3_transpt.
DR   InterPro; IPR016152; PTrfase/Anion_transptr.
DR   PANTHER; PTHR11453; PTHR11453; 1.
DR   Pfam; PF07565; Band_3_cyto; 1.
DR   Pfam; PF00955; HCO3_cotransp; 1.
DR   PRINTS; PR01231; HCO3TRNSPORT.
DR   PRINTS; PR01232; NAHCO3TRSPRT.
DR   SUPFAM; SSF55804; SSF55804; 1.
DR   TIGRFAMs; TIGR00834; ae; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Ion transport;
KW   Membrane; Phosphoprotein; Reference proteome; Retinitis pigmentosa;
KW   Sodium; Sodium transport; Symport; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN         1   1079       Electrogenic sodium bicarbonate
FT                                cotransporter 1.
FT                                /FTId=PRO_0000079227.
FT   TOPO_DOM      1    468       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    469    488       Helical. {ECO:0000255}.
FT   TOPO_DOM    489    504       Extracellular. {ECO:0000255}.
FT   TRANSMEM    505    526       Helical. {ECO:0000255}.
FT   TOPO_DOM    527    554       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    555    580       Helical. {ECO:0000255}.
FT   TOPO_DOM    581    691       Extracellular. {ECO:0000255}.
FT   TRANSMEM    692    710       Helical. {ECO:0000255}.
FT   TOPO_DOM    711    725       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    726    748       Helical. {ECO:0000255}.
FT   TOPO_DOM    749    777       Extracellular. {ECO:0000255}.
FT   TRANSMEM    778    797       Helical. {ECO:0000255}.
FT   TOPO_DOM    798    822       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    823    847       Helical. {ECO:0000255}.
FT   TOPO_DOM    848    881       Extracellular. {ECO:0000255}.
FT   TRANSMEM    882    901       Helical. {ECO:0000255}.
FT   TOPO_DOM    902    949       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    950    967       Helical. {ECO:0000255}.
FT   TOPO_DOM    968    970       Extracellular. {ECO:0000255}.
FT   TRANSMEM    971    986       Helical. {ECO:0000255}.
FT   TOPO_DOM    987   1079       Cytoplasmic. {ECO:0000255}.
FT   REGION        1     62       Required for interaction with AHCYL1.
FT                                {ECO:0000269|PubMed:16769890}.
FT   REGION      748    779       Interaction with CA4.
FT   REGION     1002   1004       CA2-binding.
FT   REGION     1030   1033       CA2-binding.
FT   REGION     1057   1059       Required for basolateral targeting.
FT   COMPBIAS   1009   1024       Lys-rich.
FT   MOD_RES      30     30       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES      49     49       Phosphothreonine; by PKA.
FT                                {ECO:0000269|PubMed:12730338}.
FT   MOD_RES      61     61       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES      65     65       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES      68     68       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES     223    223       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES     232    232       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES     233    233       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES     245    245       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES     249    249       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9JI66}.
FT   MOD_RES     254    254       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     256    256       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES     257    257       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     262    262       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES    1026   1026       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:11744745}.
FT   MOD_RES    1029   1029       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES    1034   1034       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1044   1044       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88343}.
FT   MOD_RES    1069   1069       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9JI66}.
FT   CARBOHYD    641    641       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:25568315}.
FT   CARBOHYD    661    661       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:25568315}.
FT   DISULFID    627    629       {ECO:0000269|PubMed:25568315}.
FT   DISULFID    674    686       {ECO:0000269|PubMed:25568315}.
FT   VAR_SEQ       1     44       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9235899}.
FT                                /FTId=VSP_016704.
FT   VAR_SEQ      45     85       HKRKTGHKEKKEKERISENYSDKSDIENADESSSSILKPLI
FT                                -> MSTENVEGKPSNLGERGRARSSTFLRVVQPMFNHSIFT
FT                                SAV (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9235899}.
FT                                /FTId=VSP_016705.
FT   VAR_SEQ     635    690       ANISISNDTTLAPEYLPTMSSTDMYHNTTFDWAFLSKKECS
FT                                KYGGNLVGNNCNFVP -> GEGITLCVYARFVFGGRCRLHA
FT                                CKFSTCCHGPQELVLFFSLKNSATEFDVSLPEVF (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_016706.
FT   VAR_SEQ     691   1079       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_016707.
FT   VAR_SEQ     813    896       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_016708.
FT   VAR_SEQ    1034   1079       SDCPYSEKVPSIKIPMDIMEQQPFLSDSKPSDRERSPTFLE
FT                                RHTSC -> EKDHQHSLNATHHADKIPFLQSLGMPSPPRTP
FT                                VKVVPQIRIELEPEDNDYFWRSKGTETTL (in isoform
FT                                5). {ECO:0000303|Ref.6}.
FT                                /FTId=VSP_041003.
FT   VARIANT     342    342       R -> S (in pRTA-OA; decreased
FT                                localization to the basolateral membrane;
FT                                mistargeting to the apical membrane
FT                                probably explains the loss of the
FT                                cotransporter activity;
FT                                dbSNP:rs121908856).
FT                                {ECO:0000269|PubMed:10545938,
FT                                ECO:0000269|PubMed:15713912,
FT                                ECO:0000269|PubMed:15930088,
FT                                ECO:0000303|PubMed:17661077}.
FT                                /FTId=VAR_024751.
FT   VARIANT     471    471       S -> L (in pRTA-OA; mistargeting to the
FT                                apical membrane and altered function).
FT                                {ECO:0000269|PubMed:15471865,
FT                                ECO:0000269|PubMed:15713912}.
FT                                /FTId=VAR_024752.
FT   VARIANT     529    529       T -> S (in pRTA-OA; decreased
FT                                cotransporter activity).
FT                                {ECO:0000269|PubMed:15930088,
FT                                ECO:0000303|PubMed:17661077}.
FT                                /FTId=VAR_024753.
FT   VARIANT     530    530       G -> R (in pRTA-OA; decreased
FT                                cotransporter activity; no effect on
FT                                localization to the basolateral
FT                                membrane). {ECO:0000303|PubMed:17661077}.
FT                                /FTId=VAR_071661.
FT   VARIANT     554    554       R -> H (in pRTA-OA; mistargeting and
FT                                altered function; dbSNP:rs121908857).
FT                                {ECO:0000269|PubMed:10545938,
FT                                ECO:0000269|PubMed:15713912,
FT                                ECO:0000269|PubMed:15930088}.
FT                                /FTId=VAR_024754.
FT   VARIANT     566    566       L -> P (in pRTA-OA; loss of localization
FT                                to the plasma membrane; the retention in
FT                                the cytoplasm probably explains the loss
FT                                of the cotransporter activity).
FT                                {ECO:0000269|PubMed:16636648,
FT                                ECO:0000303|PubMed:17661077}.
FT                                /FTId=VAR_071662.
FT   VARIANT     843    843       A -> V (in pRTA-OA; altered function).
FT                                {ECO:0000269|PubMed:15930088}.
FT                                /FTId=VAR_024755.
FT   VARIANT     925    925       R -> C (in pRTA-OA; altered function).
FT                                {ECO:0000269|PubMed:15930088}.
FT                                /FTId=VAR_024756.
FT   MUTAGEN      49     49       T->A: Loss of conductance regulation by
FT                                cAMP; isoform 1.
FT                                {ECO:0000269|PubMed:12730338}.
FT   MUTAGEN      49     49       T->D: Loss of conductance regulation by
FT                                cAMP; isoform 1.
FT                                {ECO:0000269|PubMed:12730338}.
FT   MUTAGEN     135    135       E->R: Mistargeting and altered function.
FT                                {ECO:0000269|PubMed:15713912}.
FT   MUTAGEN     477    477       Y->F: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     493    493       D->N: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     494    494       A->K: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     503    503       E->Q: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     504    504       S->L: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     536    536       E->Q: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     552    552       E->N: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     554    554       R->D: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     582    582       R->N: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     582    582       R->Q: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     586    586       E->Q: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     599    599       D->N: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     600    600       A->T: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     602    602       K->Q: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     603    603       K->Q: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     691    691       D->R: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     700    700       F->M: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     711    711       K->E,N,Q: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     711    711       K->R: No effect on the sodium-dependent
FT                                ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     712    712       K->N: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     714    714       K->Q: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     715    715       T->N: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     721    721       T->G: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     724    724       R->E: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     725    725       K->N: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     728    728       S->G: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     729    729       D->N,R: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     743    743       D->K,N: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     749    749       D->N: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     752    752       K->Q: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     766    766       R->Q: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     767    767       G->T: Alters interaction with CA4.
FT                                {ECO:0000269|PubMed:14567693}.
FT   MUTAGEN     775    775       E->N: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     798    798       D->E,N,R: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     808    809       RK->NN: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     814    815       KK->NN: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     820    820       H->D,N,S,R: Moderate reduction of the
FT                                sodium-dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     822    822       D->N: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     851    851       H->N: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     853    853       D->N: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     858    860       ETE->MSK: Moderate reduction of the
FT                                sodium-dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     875    877       EQR->QQQ: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     875    875       E->Q: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT   MUTAGEN     898    898       K->E: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     925    927       RLK->NLN: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     948    948       R->E: Strong reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     949    949       R->E: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     951    951       H->D: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     951    951       H->N,R: Prevents membrane targeting.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     968    968       K->Q: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN     987    987       R->E,N: Moderate reduction of the sodium-
FT                                dependent ion transport activity.
FT                                {ECO:0000269|PubMed:15817634}.
FT   MUTAGEN    1002   1002       L->N: Partial loss of interaction with
FT                                CA2. {ECO:0000269|PubMed:15218065}.
FT   MUTAGEN    1003   1003       D->N: Abolishes interaction with CA2.
FT                                {ECO:0000269|PubMed:15218065}.
FT   MUTAGEN    1004   1004       D->N: Partial loss of interaction with
FT                                CA2. {ECO:0000269|PubMed:15218065}.
FT   MUTAGEN    1026   1026       S->A: Prevents phosphorylation by PKA.
FT                                Loss of regulation by cAMP of the
FT                                transporter stoichiometry.
FT                                {ECO:0000269|PubMed:11744745,
FT                                ECO:0000269|PubMed:12730338}.
FT   MUTAGEN    1026   1026       S->D: Loss of regulation by cAMP of the
FT                                transporter stoichiometry. Shifts
FT                                transporter stoichiometry from 3:1 to
FT                                2:1. {ECO:0000269|PubMed:11744745,
FT                                ECO:0000269|PubMed:12730338}.
FT   MUTAGEN    1030   1033       DNDD->NNNN: Abolishes interaction with
FT                                CA2. {ECO:0000269|PubMed:15218065}.
FT   MUTAGEN    1030   1030       D->N: Loss of regulation by cAMP of the
FT                                transporter stoichiometry. Abolishes
FT                                interaction with CA2.
FT                                {ECO:0000269|PubMed:12411514}.
FT   MUTAGEN    1032   1032       D->N: Loss of regulation by cAMP of the
FT                                transporter stoichiometry. Partial loss
FT                                of interaction with CA2.
FT                                {ECO:0000269|PubMed:12411514}.
FT   MUTAGEN    1033   1033       D->N: No effect on regulation by cAMP of
FT                                the transporter stoichiometry. Partial
FT                                loss of interaction with CA2.
FT                                {ECO:0000269|PubMed:12411514}.
FT   MUTAGEN    1057   1057       F->A: Targeting to apical membrane.
FT                                {ECO:0000269|PubMed:15273250}.
FT   CONFLICT      6      6       V -> A (in Ref. 4; AAG47773).
FT                                {ECO:0000305}.
FT   CONFLICT     49     49       T -> A (in Ref. 6; BAH58226).
FT                                {ECO:0000305}.
FT   CONFLICT     78     78       S -> G (in Ref. 3; AAF21718).
FT                                {ECO:0000305}.
FT   CONFLICT    256    256       S -> F (in Ref. 3; AAD42020).
FT                                {ECO:0000305}.
FT   CONFLICT    263    263       D -> E (in Ref. 3; AAF21718).
FT                                {ECO:0000305}.
FT   CONFLICT    298    298       P -> H (in Ref. 6; BAH58226).
FT                                {ECO:0000305}.
FT   CONFLICT    364    364       H -> R (in Ref. 3; AAF21719).
FT                                {ECO:0000305}.
FT   CONFLICT    605    605       I -> V (in Ref. 3; AAF21718).
FT                                {ECO:0000305}.
FT   CONFLICT    654    654       S -> P (in Ref. 3; AAF21718).
FT                                {ECO:0000305}.
FT   CONFLICT    749    749       D -> G (in Ref. 3; AAF21719).
FT                                {ECO:0000305}.
FT   CONFLICT    799    799       Q -> R (in Ref. 4; AAG47773).
FT                                {ECO:0000305}.
FT   CONFLICT    856    856       K -> R (in Ref. 4; AAG47773).
FT                                {ECO:0000305}.
FT   CONFLICT    912    912       M -> R (in Ref. 3; AAF21718).
FT                                {ECO:0000305}.
FT   CONFLICT    913    913       G -> R (in Ref. 3; AAF21719).
FT                                {ECO:0000305}.
FT   CONFLICT    940    940       I -> V (in Ref. 3; AAF21718).
FT                                {ECO:0000305}.
FT   CONFLICT   1007   1007       P -> S (in Ref. 3; AAF21719).
FT                                {ECO:0000305}.
FT   CONFLICT   1069   1069       S -> P (in Ref. 3; AAF21719).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1079 AA;  121461 MW;  14B981A94DD64293 CRC64;
     MEDEAVLDRG ASFLKHVCDE EEVEGHHTIY IGVHVPKSYR RRRRHKRKTG HKEKKEKERI
     SENYSDKSDI ENADESSSSI LKPLISPAAE RIRFILGEED DSPAPPQLFT ELDELLAVDG
     QEMEWKETAR WIKFEEKVEQ GGERWSKPHV ATLSLHSLFE LRTCMEKGSI MLDREASSLP
     QLVEMIVDHQ IETGLLKPEL KDKVTYTLLR KHRHQTKKSN LRSLADIGKT VSSASRMFTN
     PDNGSPAMTH RNLTSSSLND ISDKPEKDQL KNKFMKKLPR DAEASNVLVG EVDFLDTPFI
     AFVRLQQAVM LGALTEVPVP TRFLFILLGP KGKAKSYHEI GRAIATLMSD EVFHDIAYKA
     KDRHDLIAGI DEFLDEVIVL PPGEWDPAIR IEPPKSLPSS DKRKNMYSGG ENVQMNGDTP
     HDGGHGGGGH GDCEELQRTG RFCGGLIKDI KRKAPFFASD FYDALNIQAL SAILFIYLAT
     VTNAITFGGL LGDATDNMQG VLESFLGTAV SGAIFCLFAG QPLTILSSTG PVLVFERLLF
     NFSKDNNFDY LEFRLWIGLW SAFLCLILVA TDASFLVQYF TRFTEEGFSS LISFIFIYDA
     FKKMIKLADY YPINSNFKVG YNTLFSCTCV PPDPANISIS NDTTLAPEYL PTMSSTDMYH
     NTTFDWAFLS KKECSKYGGN LVGNNCNFVP DITLMSFILF LGTYTSSMAL KKFKTSPYFP
     TTARKLISDF AIILSILIFC VIDALVGVDT PKLIVPSEFK PTSPNRGWFV PPFGENPWWV
     CLAAAIPALL VTILIFMDQQ ITAVIVNRKE HKLKKGAGYH LDLFWVAILM VICSLMALPW
     YVAATVISIA HIDSLKMETE TSAPGEQPKF LGVREQRVTG TLVFILTGLS VFMAPILKFI
     PMPVLYGVFL YMGVASLNGV QFMDRLKLLL MPLKHQPDFI YLRHVPLRRV HLFTFLQVLC
     LALLWILKST VAAIIFPVMI LALVAVRKGM DYLFSQHDLS FLDDVIPEKD KKKKEDEKKK
     KKKKGSLDSD NDDSDCPYSE KVPSIKIPMD IMEQQPFLSD SKPSDRERSP TFLERHTSC
//
